Literature DB >> 24218521

Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.

Akira Hirasawa1, Kenta Masuda, Tomoko Akahane, Arisa Ueki, Megumi Yokota, Tomohiko Tsuruta, Hiroyuki Nomura, Fumio Kataoka, Eiichiro Tominaga, Kouji Banno, Kazuya Makita, Nobuyuki Susumu, Kokichi Sugano, Kenjiro Kosaki, Kaori Kameyama, Daisuke Aoki.   

Abstract

BACKGROUND: This study aimed to examine family history among Japanese ovarian cancer patients and to investigate the TP53 status of fallopian tube epithelial and ovarian cancer cells in a Japanese BRCA1 mutant case that may be associated with the transformed state in hereditary ovarian cancer.
METHODS: One hundred and two primary ovarian cancer patients were retrospectively evaluated in this cross-sectional study. The family history of cancer was determined in probands. In a BRCA1 mutant case, p53 immunostaining and direct sequencing, followed by laser-capture microdissection, were performed for the fallopian tube, considered the origin of ovarian cancer.
RESULTS: Nine of 102 (8.8%) families were regarded as having hereditary breast-ovarian cancer syndrome, two families (2.0%) were diagnosed with Lynch syndrome and six patients harbored BRCA1 or BRCA2 mutations. One case underwent risk-reductive salpingo-oophorectomy as a BRCA1 mutant carrier was retrospectively diagnosed as occult cancer. Common TP53 mutations were detected in cancer and fallopian tube epithelial cells in the case.
CONCLUSIONS: Here, we integrate family cancer history and histology in ovarian cancer cases as well as TP53 status in a BRCA1 mutant case into a discussion regarding carcinogenesis in a Japanese population. The TP53 status for the BRCA1 mutant case examined here supports the recently proposed theory that ovarian cancer develops because of BRCA1 or BRCA2 inactivation and/or TP53 mutations.

Entities:  

Keywords:  Lynch syndrome; fallopian tube epithelium; family history; hereditary breast–ovarian cancer; occult cancer; ovarian cancer; p53 signature; risk-reducing salpingo-oophorectomy

Mesh:

Substances:

Year:  2013        PMID: 24218521     DOI: 10.1093/jjco/hyt171

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

1.  TP53 variants in p53 signatures and the clonality of STICs in RRSO samples.

Authors:  Tomoko Akahane; Kenta Masuda; Akira Hirasawa; Yusuke Kobayashi; Arisa Ueki; Miho Kawaida; Kumiko Misu; Kohei Nakamura; Shimpei Nagai; Tatsuyuki Chiyoda; Wataru Yamagami; Shigenori Hayashi; Fumio Kataoka; Kouji Banno; Kokichi Sugano; Hajime Okita; Kenjiro Kosaki; Hiroshi Nishihara; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2022-03-21       Impact factor: 4.756

2.  Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.

Authors:  Angel Chao; Ting-Chang Chang; Nina Lapke; Shih-Ming Jung; Peter Chi; Chien-Hung Chen; Lan-Yan Yang; Cheng-Tao Lin; Huei-Jean Huang; Hung-Hsueh Chou; Jui-Der Liou; Shu-Jen Chen; Tzu-Hao Wang; Chyong-Huey Lai
Journal:  Oncotarget       Date:  2016-12-20

3.  Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.

Authors:  Akira Hirasawa; Issei Imoto; Takuya Naruto; Tomoko Akahane; Wataru Yamagami; Hiroyuki Nomura; Kiyoshi Masuda; Nobuyuki Susumu; Hitoshi Tsuda; Daisuke Aoki
Journal:  Oncotarget       Date:  2017-11-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.